112 related articles for article (PubMed ID: 28032649)
1. KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.
Tang FH; Hsieh TH; Hsu CY; Lin HY; Long CY; Cheng KH; Tsai EM
Int J Cancer; 2017 Apr; 140(8):1860-1869. PubMed ID: 28032649
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.
Chiba Y; Sato S; Itamochi H; Suga Y; Fukagawa T; Oumi N; Oishi T; Harada T; Sugai T; Sugiyama T
Hum Cell; 2017 Apr; 30(2):140-148. PubMed ID: 27889902
[TBL] [Abstract][Full Text] [Related]
3. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 expression in fallopian tube epithelium drives cell migration.
Quartuccio SM; Karthikeyan S; Eddie SL; Lantvit DD; Ó hAinmhire E; Modi DA; Wei JJ; Burdette JE
Int J Cancer; 2015 Oct; 137(7):1528-38. PubMed ID: 25810107
[TBL] [Abstract][Full Text] [Related]
5. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.
Dinulescu DM; Ince TA; Quade BJ; Shafer SA; Crowley D; Jacks T
Nat Med; 2005 Jan; 11(1):63-70. PubMed ID: 15619626
[TBL] [Abstract][Full Text] [Related]
6. Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells.
Motohara T; Masuko S; Ishimoto T; Yae T; Onishi N; Muraguchi T; Hirao A; Matsuzaki Y; Tashiro H; Katabuchi H; Saya H; Nagano O
Carcinogenesis; 2011 Nov; 32(11):1597-606. PubMed ID: 21828057
[TBL] [Abstract][Full Text] [Related]
7. [Carcinosarcomas of the uterus: molecular-genetic and morphological features].
Levitskaia NV; Pozharisskiĭ KM; Vostriukhina OA; Alekseeva LN; Nemtsova MV; Matrosova IV; Kharitonova TV; Poddubnaia IV
Arkh Patol; 2012; 74(1):7-11. PubMed ID: 22712296
[TBL] [Abstract][Full Text] [Related]
8. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of epithelial ovarian cancer.
Christie M; Oehler MK
J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
[TBL] [Abstract][Full Text] [Related]
10. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE
Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2008 Apr; 27(2):151-60. PubMed ID: 18317228
[TBL] [Abstract][Full Text] [Related]
12. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
13. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
Xing D; Orsulic S
Cancer Res; 2006 Sep; 66(18):8949-53. PubMed ID: 16982732
[TBL] [Abstract][Full Text] [Related]
14. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
15. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
16. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour.
Bai Q; Zhang X; Zhu X; Wang L; Huang D; Cai X; Zhou X; Wang J; Sheng W
Histopathology; 2016 Sep; 69(3):393-405. PubMed ID: 27307095
[TBL] [Abstract][Full Text] [Related]
18. Methods to generate genetically engineered mouse models of soft tissue sarcoma.
Dodd RD; Añó L; Blum JM; Li Z; Van Mater D; Kirsch DG
Methods Mol Biol; 2015; 1267():283-95. PubMed ID: 25636474
[TBL] [Abstract][Full Text] [Related]
19. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
[TBL] [Abstract][Full Text] [Related]
20. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
